Document is current
Any future updates will be listed below
-
Authors
Reese, Justin T.
Coleman, Ben
Chan, Lauren
Blau, Hannah
Callahan, Tiffany J.
Cappelletti, Luca
Fontana, Tommaso
Bradwell, Katie R.
Harris, Nomi L.
Casiraghi, Elena
Valentini, Giorgio
Karlebach, Guy
Deer, Rachel
McMurry, Julie A.
Haendel, Melissa A.
Chute, Christopher G.
Pfaff, Emily
Moffitt, Richard
Spratt, Heidi
Singh, Jasvinder A.
Mungall, Christopher J.
Williams, Andrew E.
Robinson, Peter N. http://orcid.org/0000-0002-0736-9199
-
Funding
Funding for this research was provided by:
Office of Science (DE-AC02-05CH11231, DE-AC02-05CH11231, DE-AC02-05CH11231)
Institute for Translational Sciences, University of Texas Medical Branch (2P30AG024832-16)
National Institutes of Health (U24 TR002306, NIH UL1TR001439)
National Center for Advancing Translational Sciences (NCATS U24 TR002306)
- License Information
-
More Information
Article History
Received: 23 December 2021
Accepted: 4 May 2022
First Online: 15 May 2022
Declarations
:
: The N3C data transfer to NCATS is performed under a Johns Hopkins University Reliance Protocol #IRB00249128 or individual site agreements with NIH. The N3C Data Enclave is managed under the authority of the NIH; information can be found at .
: Not applicable.
: Katie Rebecca Bradwell: employee of Palantir Technologies; Melissa A. Haendel: co-founder Pryzm Health; Julie A. McMurry: Cofounder, Pryzm Health; Jasvinder Singh: JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc, Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, and Practice Point communications; and the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in TPT Global Tech, Vaxart pharmaceuticals and Charlotte’s Web Holdings, Inc. JAS previously owned stock options in Amarin, Viking and Moderna pharmaceuticals. JAS is on the speaker’s bureau of Simply Speaking. JAS is a member of the executive of Outcomes Measures in Rheumatology (OMERACT), an organization that develops outcome measures in rheumatology and receives arms-length funding from 12 companies.
